3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
12
Pheochromocytoma
4
Neoplasms
3
Recurrence
2
Paraganglioma
2
Neuroendocrine Tumors
2
Neuroectodermal Tumors
1
Neoplasm Metastasis
1
Ganglioneuroblastoma
1
Interventions
pembrolizumab
1
cixutumumab
1
Vorinostat
1
Temozolomide
1
Sunitinib
1
Oncolytic Virotherapy
1
Erlotinib Hydrochloride
1
Antibodies, Monoclonal
1
3-Iodobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroectodermal Tumors
×
3-Iodobenzylguanidine
×
Clear all
NCT03561259
2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2
Unknown
60 enrolled